WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer

NAPA, California - Dr. Vinocur Reports on University of California Rosacea-Specific Study -

On March 9, 2009, Dr. Leigh Vinocur, medical expert from the University
of Maryland School of Medicine, was featured on WBAL-AM 1090 in a segment on
rosacea, a condition afflicting over 14 million Americans. Dr. Vinocur
addressed current therapies while reporting on a new study conducted at the
Department of Dermatology, University of California, Irvine, in which rosacea
patients were treated with a new cosmeceutical, Pyratine XR(TM) (0.125%
furfuryl tetrahydropyranyl adenine).

Rosacea is a chronic skin disorder characterized by dilated blood vessels
on the face, redness, inflammation, and lesions (papules and pustules).
According to Dr. Vinocur, traditional treatments for rosacea focus on topical
and oral antibiotics for their anti-inflammatory properties, but the new
study showed that cytokinins, natural plant-derived growth factors known for
their antioxidant and moisture retention benefits, appear to significantly
reduce rosacea symptoms.

Over the 48-week study with Pyratine XR(TM) there was an overall clinical
improvement in 80% of subjects with a 90% improvement in lesions, 45%
improvement in redness, and a 28% improvement in spider veins. The product
also appeared to improve the skin barrier function with a 41% improvement in
skin dryness as early as week four while appearing to concurrently reduce
fine lines, wrinkles and hyperpigmentation.

Pyratine XR(TM) is manufactured by Senetek PLC
(OTC Bulletin Board: SNKTY), a life sciences company engaged in the
development of technologies that target the science of healthy aging.
Pyratine XR(TM) officially launched at the American Academy of Dermatology’s
67th Annual Meeting in San Francisco, March 6-10, 2009.

For more information on Pyratine XR(TM), please visit www.PyratineXR.com.

About Senetek, PLC

Senetek PLC (OTCBB: SNKTY) is a life sciences company engaged in the
development of breakthrough technologies that target the science of healthy
aging. The company’s extensive research collaborations have resulted in a
strong pipeline of patented compounds and products with broad therapeutic
applications and a leading presence in dermatology. Senetek collaborates with
established specialty pharmaceutical companies in the final development and
marketing of its proprietary products, most recently resulting in the
development of kinetin, the best-selling anti-aging product sold in the North
American physician market. For more information, visit the company’s website
at www.senetekplc.com.

Source: Senetek PLC

William O’Kelly of Senetek, PLC, +1-707-226-3900, ext. 102; or Media, Michael Rogers, michael at michaelrogerspr.com, or Maggie Carr, maggie at michaelrogerspr.com, both for Senetek, PLC, +1-212-255-7210